We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
- Authors
Sugawara, Shunichi; Kondo, Masashi; Yokoyama, Toshihide; Kumagai, Toru; Nishio, Makoto; Goto, Koichi; Nakagawa, Kazuhiko; Seto, Takashi; Yamamoto, Nobuyuki; Kudou, Kentarou; Asato, Takayuki; Zhang, Pingkuan; Ohe, Yuichiro
- Abstract
Correction to: International Journal of Clinical Oncology https://doi.org/10.1007/s10147-022-... In the original publication in Table 1, the entry: "Nichirei Histofine RALK iAEP Kit" should read as: "Nichirei Histofine ALK iAEP Kit". Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
- Subjects
ANAPLASTIC lymphoma kinase; NON-small-cell lung carcinoma; PROTEIN-tyrosine kinases; JAPANESE people; REVERSE transcriptase polymerase chain reaction
- Publication
International Journal of Clinical Oncology, 2022, Vol 27, Issue 12, p1839
- ISSN
1341-9625
- Publication type
Correction Notice
- DOI
10.1007/s10147-022-02252-3